Provided by Tiger Trade Technology Pte. Ltd.

Aktis Oncology

17.69
-0.3100-1.72%
Volume:223.23K
Turnover:3.87M
Market Cap:977.83M
PE:-12.93
High:17.86
Open:17.86
Low:16.99
Close:18.00
52wk High:34.19
52wk Low:14.72
Shares:55.28M
Float Shares:17.65M
Volume Ratio:0.95
T/O Rate:1.26%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3680
EPS(LYR):-78.3394
ROE:-29.45%
ROA:-15.79%
PB:2.02
PE(LYR):-0.23

Loading ...

Wedbush Reaffirms Their Buy Rating on Aktis Oncology, Inc. (AKTS)

TIPRANKS
·
Oct 05

Aktis Oncology Price Target Maintained with a $35.00/Share by Wedbush

Dow Jones
·
Oct 02

Aktis Oncology Initiates Second Phase 1B Clinical Trial for Aky-2519, a Miniprotein Radioconjugate Targeting B7-H3

THOMSON REUTERS
·
Oct 01

Aktis Oncology - Preliminary Data from Phase 1B Bactinium-1 Trial Expected in 2027

THOMSON REUTERS
·
Oct 01

Aktis Oncology Initiates Second Phase 1b Clinical Trial for AKY-2519, a Miniprotein Radioconjugate Targeting B7-H3

GlobeNewswire
·
Oct 01

Aktis Oncology CMO Akos Czibere Disposes of Common Shares Worth $262,848.71

Reuters
·
Sep 25

Aktis Oncology Initiated at Outperform by Oppenheimer

Dow Jones
·
Sep 09

Aktis Oncology Inc : Oppenheimer Initiates Coverage with Outperform Rating; Price Target $40

THOMSON REUTERS
·
Sep 09

Oppenheimer Initiates Coverage on Akoustis Technologies With Outperform Rating, $40 PT

MT Newswires Live
·
Sep 09

Aktis Oncology to Present at Upcoming September Investor Conferences

GlobeNewswire
·
Sep 09

Aktis Oncology initiated with an Outperform at Oppenheimer

TIPRANKS
·
Sep 09

U.S. Research Roundup-Argan, Mastec, Oracle

Reuters
·
Sep 09

Aktis Oncology Seen Advancing Targeted Radiation-Based Cancer Drugs, Wedbush Says

MT Newswires Live
·
Aug 19

Wedbush Initiates Aktis Oncology at Outperform With $35 Price Target

MT Newswires Live
·
Aug 19

Aktis Oncology initiated with an Outperform at Wedbush

TIPRANKS
·
Aug 19

Aktis Oncology Inc : Bmo Initiates Coverage with Outperform Rating; Price Target $37

THOMSON REUTERS
·
Aug 19

16 Beaten-Down AI Stocks That Are Beloved by BofA Analysts

Dow Jones
·
Aug 17

Cancer Diagnostics Firm Precipio's Q2 Revenue Rises, Adjusted Ebitda Turns Positive

Reuters
·
Aug 15

Moleculin Biotech Expects Cash Position to Fund Operations into Q1 2027

Reuters
·
Aug 14

Analysts Have Conflicting Sentiments on These NA Companies: Aktis Oncology, Inc. (AKTS), Bullish (BLSH) and SanDisk Corp (SNDK)

TIPRANKS
·
Aug 14